Kornimate/medical-research-clean huggingface dataset:
use of saline-washed platelet and red cell transfusions in adult acute leukemia

Conditions: Leukemia, Myeloid, Acute; Leukemia, Lymphoblastic, Acute

Summary: the purpose of this study is to determine whether a novel standard of care protocol, washing red cell and platelet transfusions for younger patients with acute leukemia, has yielded improved clinical outcomes at strong memorial hospital (rochester, new york, usa). this standard of care was implemented based upon an earlier randomized trial (bmc blood disorders. 2004 dec 10;4(1):6) the comparator will be historical controls from the medical literature.

the purpose of this study is to determine whether a novel standard of care protocol, washing red cell and platelet transfusions for younger patients with acute leukemia, has yielded improved clinical outcomes at strong memorial hospital (rochester, new york, usa). this standard of care was implemented based upon an earlier randomized trial (bmc blood disorders. 2004 dec 10;4(1):6) the comparator will be historical controls from the medical literature. key outcomes will be treatment related mortality (deaths at 30, 60 and 100 days) and three year survival.

Eligibility criteria:
inclusion criteria: * previously untreated patients with a diagnosis of acute leukemia between the ages of 0 and 50 (aml) and 18 and 50 (all) exclusion criteria: * all other patients

Keywords: leukemia transfusion
evaluation of dry eye and meibomian gland dysfunction after cataract surgery

Conditions: Meibomian Gland Dysfunction

Summary: meibomian gland dysfunction (mgd) is a common and important disease has been investigated the pathophysiology, diagnosis, treatment modalities of mgd, however, the changes of mgd after the cataract surgery, the most popular surgery to ophthalmologist, had not been evaluated. the investigators evaluated parameters related with mgd including lid margin abnormalities, meibomian gland expressibility and meibography before and after surgery.


Eligibility criteria:
inclusion criteria: 1. patients scheduled for cataract surgery exclusion criteria: 1. other comorbid ocular diseases such as ocular allergies. 2. continuous use of topical ocular medications before surgery 3. histories of ocular surgery, or ocular injury 4. already had severe obstructive mgd before surgery, abnormal findings on lid margin (\> 3 positive findings), reduced meibum expression (\> grade 2), and obstructed gland dropout (meibography score \> 3)

Keywords: cataract surgery, meibomian gland dysfunction, meibum expressibility, meibography
clinical study for the evaluation of the safety and initial performance of the clearring system for the treatment of benign prostatic hyperplasia

Conditions: Benign ProstaticHyperplasia (BPH)

Summary: the proarc medical clearring™ system is a prostatic reshaping device that is designed to treat lower urinary tract symptoms (luts) due to bph. during the procedure an implant is delivered into the prostate tissue obstructing the urethra and restricting urine flow. the delivery system uses an electro-cutting blade to perform a circular and superficial incision, in which the implant is placed. such an implant, with the shape of an open ring, expands the obstructed area, reducing the fluid obstruction through the prostatic urethra.

the proposed study will be conducted on bph patients, candidates for turp and will aim to evaluate the ability of the clearring™ to improve bph symptoms while conforming to safety of the procedure. in the proposed study the implants will be inserted by a dedicated delivery system with the aid of resectoscope. electrical current will be administered by off-the-shelf ce mark diathermy that passes through the system to cut and pave the ring course. the proper positioning of the implants will be evaluated by cystoscopy or trus and following implant positioning the device will be withdrawn. the delivery tool, the implants, resectoscope and the diathermy equipment will be supplied by proarc ltd.

Eligibility criteria:
inclusion criteria: 1. male 50 years of age and up to 85 years old. 2. diagnosed with symptomatic benign prostatic hyperplasia (bph) 3. international prostate symptom score (ipss) \>13 4. peak flow rate ≤ 12 ml/sec (with voided volume ≥ 125ml) 5. subject is in good general health. 6. subject understands and has signed the study informed consent form. 7. psa according to the american urological association) aua) guideline. exclusion criteria: 1. subjects who are known to be infected with hepatitis b, hepatitis c, or hiv viruses. 2. subject allergic to nickel or titanium 3. concomitant participation in another study 4. diagnosed with cancer except of bcc or scc of the skin 5. any medical condition at the investigator discretion that may interfere with the procedure. 6. patient with coagulopathy due to medications or congenital 7. patient is taking steroids 8. previous prostate surgery 9. compromised renal function due to obstructive uropathy 10. urinary tract infection (uti) 11. intravesical lobe (based on ultrasound and/or cystoscopy and/or medical history) 12. prostate volume (based on trans rectal ultrasound) \> 80g 13. american society of anesthesiologists score (asa)≥3 14. known neurogenic bladder 15. implanted electronic device such as pacemaker/crt/icd/dbs. 16. recent myocardial infarction (less than three months)
study of the effect of synchronised anaemia management in chronic kidney disease

Conditions: Kidney Failure, Chronic; Anemia

Summary: aims: 1. to establish an electronic process for ckd anaemia management using monthly synchronized dosing of erythrocyte stimulating agents (esa). 2. to compare this electronic process with "present anaemia management" in the traditional outpatient setting. 3. to monitor hb targets and clinical endpoints of study groups to model a larger multicentre study focusing on these endpoints.

ckd stages 3 to 5 subjects will be randomised and stratified according to age, gender, ckd stage, known cardiovascular disease, diabetes and esa type into eman vs. control details of eman synchronization and dosing: monthly dose of esa is calculated by: monthly dose = present dose x (28/present frequency (days)) synchronization will be achieved by using the formula: "synchronization dose of esa = (28-days until next injection is due)/28 x monthly dose of esa the dose of esa/c.e.r.a. should be adjusted to maintain the individual patient's haemoglobin within a range of 11± 1.0 g/dl of the reference haemoglobin concentration ie. between 10.0 and 12.0 g/dl haemoglobin value corrective adjustment * a single value \>13 g/dl interrupt treatment until hb falls below 12 g/dl then re-start treatment at 50% of previous dose * a single value \<9 g/dl increase dose by 50% * difference between two consecutive hb values indicates ≥2 g/dl increase reduce dose by 50% * difference between two consecutive hb values indicates ≥2 g/dl decrease increase dose by 50% * \>11.5 g/dl and \ 1g/dl. reduce dose by 25% * \ 9 g/dl and deviation from reference value is \>1g/dl. increase dose by 25% * \>12 g/dl reduce dose by 25% * \<10 g/dl increase dose by 25% statistics: audit of present practice suggests ckd patients achieve only 30% on target (hb 10-12g/dl) while well audited dialysis units in our service can achieve 60% at target. if an improvement from 30% to 60% is expected in the eman verses control arm then 100 patients (50 in each group) would be required to show a significant difference p\<0.05 with 85% power. patients will be analysed on an intention to treat basis primary and secondary endpoint data will be compared between study and control groups using unpaired student t-tests after normalisation of data as required and/or chi squared analysis. statistical significance will be taken at p\<0.05.

Eligibility criteria:
inclusion criteria: * written informed consent * age \> 18 years * chronic renal anaemia already on esa therapy as defined by pharmaceutical benefits scheme criteria exclusion criteria: * pregnancy * significant acute bleeding such as overt gastrointestinal bleeding * a known haematological cause for anaemia * known metastatic malignancy * present participation in another interventional clinical trial • known hypersensitivity to recombinant human erythropoietin, polyethylene glycol or to any constituent of the study medication

Keywords: ckd, anaemia, synchronization, monthly dosing, home delivery
treatment of anxiety/depression and pain through relaxation yoga for patient with cystic fibrosis (cf)

Conditions: Cystic Fibrosis

Summary: the investigators research question is whether or not yoga effectively alleviates symptoms of pain, sleep disturbance, anxiety and depression in children with cystic fibrosis. if yoga does prove to be effective, the investigators will educate our cf population about the benefits they may experience if they choose to incorporate yoga into their cf therapy. the investigators will also go on to do further research of other complementary alternative medicine therapies. this is a pre/post-test study with 20 subjects. the subjects will serve as their own controls. each subject will participate in six yoga sessions over a ten week period. subjects' symptoms will be evaluated with the use of questionnaires. the investigators will also test cortisol levels on weeks -2, -1, 1, 6, 7, 8. cortisol is a hormone that is affected by stress. testing of cortisol throughout the study will help us determine the subjects' stress level throughout the study.

h1: the implementation of a yoga therapy program decreases symptoms of pain within our cf population. h2: the implementation of a yoga therapy program decreases symptoms of sleep disturbance within our cf population. h3: the implementation of a yoga therapy program decreases symptoms of anxiety within our cf population. h4: the implementation of a yoga therapy program decreases symptoms of depression within our cf population.

Eligibility criteria:
inclusion criteria: * positive diagnosis of cf * males or females within the ages of 9 and 18 exclusion criteria: * no positive diagnosis of cf * younger than 9 years of age or older than 18 years of age * concomitant illness or disease that may inhibit the patient's ability to participate in the study as determined by the principal investigator * the patient has participated in an investigational treatment study 30 days prior to pre-session week -2. * the patient is currently participating in yoga sessions one or more times per week.

Keywords: cf
freedom-c: oral treprostinil in combination with an endothelin receptor antagonist (era) and/or a phosphodiesterase-5 (pde-5) inhibitor for the treatment of pulmonary arterial hypertension (pah)

Conditions: Pulmonary Hypertension

Summary: this study was an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with pah who were currently receiving approved therapy for their pah (i.e., endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor). study visits occurred at 4 week intervals for 16 weeks; the key measure of efficacy was the 6-minute walk test. study procedures included routine blood tests, medical history, physical exams, disease evaluation, and exercise tests. one optional substudy was also a part of freedom-c at select centers - a hemodynamic substudy with a right heart catheterization at baseline and week 16. patients who completed all assessments for 16-weeks were also eligible to enter an open-label, extension phase study (freedom - ext).


Eligibility criteria:
inclusion criteria: * between 12 and 70 years of age, inclusive. * body weight at least 45 kg (approximately 100 pounds). * pah that is either idiopathic/heritable (including pah associated with appetite suppressant/toxin use); pah associated with repaired congenital systemic-to-pulmonary shunts (repaired ≥ 5 years); pah associated with collagen vascular disease; or pah associated with hiv. * baseline 6-minute walk distance between 150 and 450 meters, inclusive. * currently receiving an approved endothelin receptor antagonist and/or an approved phosphodiesterase-5 inhibitor for at least 90 days and on a stable dose for at least the last 30 days. * previous testing (e.g., right heart catheterization, echocardiography) consistent with the diagnosis of pah. * reliable and cooperative with protocol requirements. exclusion criteria: * nursing or pregnant. * received a prostacyclin within the past 30 days. * pah due to conditions other than noted in the above inclusion criteria. * history of uncontrolled sleep apnea, renal insufficiency, anemia, left sided heart disease, uncontrolled systemic hypertension, or parenchymal lung disease. * use of an investigational drug within 30 days of baseline.

Keywords: pulmonary arterial hypertension
contingency management treatment duration

Conditions: Alcohol Abuse

Summary: 310 alcohol abusing or dependent patients beginning intensive outpatient day treatment at community-based clinics will be randomly assigned to one of four conditions: (a) standard treatment as usual (st) at the clinic without contingency management (cm); (b) standard treatment with contingency management for 12 weeks with a 0.5 probability of winning prizes for each negative sample submitted; (c) standard treatment with contingency management for 24 weeks with a 0.34 probability of winning prizes for each negative sample submitted; or (d) standard treatment with contingency management for 24 weeks with a 0.5 probability of winning prizes for each negative sample submitted. we expect that contingency management will decrease alcohol use to a greater extent than non-contingency management treatment, and that availability of contingency management for 24 weeks may result in longer term benefits than 12 week exposure to contingency management. this study will be the first to evaluate the effects of probability of winning prizes on response to contingency management.


Eligibility criteria:
inclusion criteria: * age \> 18 years * current dsm-iv diagnosis of alcohol abuse or dependence * willing to sign informed consent and able to pass an informed consent quiz exclusion criteria: * serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, severe or psychotic major depression, or suicide risk) on the basis of history or medical examination * current dsm-iv diagnosis of opioid dependence * in recovery from pathological gambling

Keywords: alcohol abuse contingency management treatment duration
reliability (test-retest) of 30 seconds sit-to-stand and timed up and go in adults with long covid

Conditions: Long COVID

Summary: the goal of this study is to test the reliability (with a test-retest process) of 30 seconds sit to stand and timed up and go in an adult population with long-covid, hospitalised in a rehabilitation center.

since december 2019, covid-19 has affected millions of people worldwide, leaving many of them with symptoms such as fatigue, (muscle) weakness and dyspnoea, even months after their infection (long covid). rehabilitation centers were established to aid this new group of patients. this study's aim is to test the reliability of 2 outcome measures for patients with long covid. 30 seconds sit-to-stand and timed up and go tests are not specific to a disease but they evaluate functionality, mobility and endurance. they are easy to perform in a clinical setting as they do not require specific equipment. the reliability of the above tests has yet to be established in people with long covid. a sample size of 19 people will be used. a difference in reliability of 0.9 and 0.7 at 80% power and a 5% level of significance using two ratings was set. based on two testing sessions, an x value of 0.05, and a power of 0.80, a minimal sample size of 19 patients was identified (karagiannis et al., 2020). 19 patients with long covid from the rehabilitation center will take both tests in a single day and 3 days later they will take the tests again with no physical therapy intervention in between the measurements. for the statistical analysis, icc (intra-class correlation coefficients), sem (standard error of measurement) and bland-altman plot will be used. these tests evaluate test-retest reliability, through the identification of the agreement of patient's scores between the 2 measurements and they evaluate the measurement precision (savva et al, 2014).

Eligibility criteria:
inclusion criteria: * adults who were infected with covid-19 virus in the last 6 months and were diagnosed with long-covid * patients must be willing to give written consent for participation in the study * negative rapid test for covid-19 exclusion criteria: * people under 18 years of age * significant cognitive and psychiatric impairments (inability to follow simple commands or give consent) * refuse to give consent

Keywords: test-retest reliability 30 seconds sit to stand timed up and go
automitochondrial transplantation improves live birth in elderly patients with low prognosis after repeated ivf failure

Conditions: Infertility, Female; Mitochondrial; Elderly; Assisted Reproductive Technique

Summary: the goal to this clinical trial is to study the effectiveness and safety of automitochondrial transplantation of urine derived stem cells(uscs) in in elderly patients with low prognosis after repeated ivf failure. the main questions it aims to answer are: (1）test the effectiveness and safety of automitochondrial transplantation of urine derived stem cells (2) establish intracytoplasmic sperm injection(icsi) mitochondrial transplantation platform participants will be asked to:1)urine collections to further culture of autologous uscs 2)ovarian stimulation、trigger eggs、icsi with autologous mitochondria 3）embryo transfer 4)accept pregnancy follow-up at given point


Eligibility criteria:
inclusion criteria: 1. 1) at least 35 years old 2. 2) repeated ivf failure: more than or equal to 2 egg retrieval with poor embryo quality, no transplanted embryos or failed embryo transfer (more than or equal to 4 embryos) 3. 3) egg number ≤9 4. 4) participate voluntarily and sign informed consent. exclusion criteria: 1: infertility caused by severe oligospermia, severe intrauterine adhesions, genital tract malformations, thyroid dysfunction and other endocrine, immune system, tumor and genetic diseases
prospective observational study of effectiveness and safety of filgotinib in participants with ulcerative colitis (uc)

Conditions: Ulcerative Colitis

Summary: to describe the effectiveness, treatment patterns, quality of life, and safety of participants with moderately or severely active uc treated with filgotinib in a real-world setting.


Eligibility criteria:
inclusion criteria: 1. filgotinib-naïve participants with moderately or severely active uc as judged by the physician and starting filgotinib treatment according to local treatment guidelines, routine practices and product information. exclusion criteria: 1. participation in any interventional or non-interventional study without prior approval from the medical leader. this does not preclude inclusion of participants enrolled to national registries. 2. participant is diagnosed with crohn's disease.

Keywords: filgotinib safety efficacy
atrial fibrillation screening with mobicare in subjects with health care examination

Conditions: Atrial Fibrillation

Summary: this study aimed to detect and diagnose atrial fibrillation early by conducting a screening test for atrial fibrillation using a continuous electrocardiography monitoring device for those who have undergone a health screening examination. early detection through atrial fibrillation screening tests in high-risk patients with stroke is intended to prevent stroke by starting stroke prevention treatment early. it is intended to detect asymptomatic atrial fibrillation patients early through examination and ultimately improve the quality of life.


Eligibility criteria:
inclusion criteria: 1. subjects aged 65 years or older who have at least one stroke risk factor\* 2. subjects aged 19 years to \<65 years who have two or more stroke risk factors. 3. subjects aged 75 years or older * stroke risk factors: heart failure, hypertension, diabetes, vascular disease, women, stroke/systemic embolism/transient ischemic attack (although stroke/systemic embolism/transient ischemic attack among stroke risk factors is considered to have two risk factors) * heart failure: a history of heart failure diagnosis or a history of current heart failure treatment. * hypertension, diabetes: diagnostic history * vascular diseases: significant coronal atherosclerosis (when 70% or more of the computed tomography or coronary angiography is present or coronary intervention is performed), 50% or more of the carotid artery disease, peripheral vascular disease, history of myocardial infarction, and aortic plaques exclusion criteria: 1. subjects diagnosed with atrial fibrillation in the past 2. subjects aged under 19 years and other vulnerable research subjects 3. subjects who have patch-type adhesive allergies/atopy dermatitis/ urticaria/skin rash/hives that are difficult to apply patches continuously 4. subjects who have a structural abnormality in the thorax and is difficult to attach the device. 5. subjects who have cardiac implantable electronic device (pacemaker, implantable cardioverter-defibrillator, implantable loop recorder, or cardiac resynchronized therapy-pacemaker or defibrillator) 6. subjects requiring immediate ecg analysis or ecg monitoring through hospitalization due to arrhythmia that can be life-threatening 7. subjects who are deemed inappropriate to participate in the research as judged by the researcher for other reasons.
effect of electrostimulation on denervated muscles in individuals with spinal cord injury

Conditions: Spinal Cord Injury

Summary: the aim of the study is to investigate whether there is an effect of electrical stimulation on the denervated gluteus muscle (buttocks) in individuals with chronic spinal cord injury. the expected outcome is an increase in muscle volume and a better pressure distribution during sitting. the stimulation of the gluteus muscle is performed daily for 35 minutes over a period of six months. the muscle volume and the pressure distribution are measured before stimulation, three months after having started stimulation and after six months.


Eligibility criteria:
inclusion criteria: * chronic spinal cord injury (min. 2 years after injury) * lesion height from t10-l5 * asia (american spinal cord injury association) impairment scale a exclusion criteria: * acute pressure sore in stimulated area (m. gluteus) * arteriosclerosis * skin irritation or infection in stimulated area (m. gluteus) * \< 3 months after plastic surgery in stimulated area (m. gluteus)